ZA977992B - Inhibition of Nuclear Transcription Factor NF-kB by Caffeic Acid Phenethyl Ester (CAPE), Derivatives of CAPE, Capsaicin (8-methyl-N-Vanillyl-6-noneamide) and Resiniferatoxin. - Google Patents

Inhibition of Nuclear Transcription Factor NF-kB by Caffeic Acid Phenethyl Ester (CAPE), Derivatives of CAPE, Capsaicin (8-methyl-N-Vanillyl-6-noneamide) and Resiniferatoxin.

Info

Publication number
ZA977992B
ZA977992B ZA9707992A ZA977992A ZA977992B ZA 977992 B ZA977992 B ZA 977992B ZA 9707992 A ZA9707992 A ZA 9707992A ZA 977992 A ZA977992 A ZA 977992A ZA 977992 B ZA977992 B ZA 977992B
Authority
ZA
South Africa
Prior art keywords
cape
noneamide
resiniferatoxin
vanillyl
capsaicin
Prior art date
Application number
ZA9707992A
Other languages
English (en)
Inventor
Bharat B Aggarwal
Dezider Grunberger
Original Assignee
Res Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Dev Foundation filed Critical Res Dev Foundation
Publication of ZA977992B publication Critical patent/ZA977992B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA9707992A 1996-09-05 1997-09-05 Inhibition of Nuclear Transcription Factor NF-kB by Caffeic Acid Phenethyl Ester (CAPE), Derivatives of CAPE, Capsaicin (8-methyl-N-Vanillyl-6-noneamide) and Resiniferatoxin. ZA977992B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2460296P 1996-09-05 1996-09-05

Publications (1)

Publication Number Publication Date
ZA977992B true ZA977992B (en) 2001-05-31

Family

ID=21821430

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9707992A ZA977992B (en) 1996-09-05 1997-09-05 Inhibition of Nuclear Transcription Factor NF-kB by Caffeic Acid Phenethyl Ester (CAPE), Derivatives of CAPE, Capsaicin (8-methyl-N-Vanillyl-6-noneamide) and Resiniferatoxin.

Country Status (8)

Country Link
US (1) US5981583A (zh)
EP (1) EP0998275A4 (zh)
JP (1) JP3987120B2 (zh)
CN (2) CN1132577C (zh)
AU (1) AU4249497A (zh)
CA (1) CA2264739C (zh)
WO (1) WO1998009620A1 (zh)
ZA (1) ZA977992B (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3002725B2 (ja) * 1998-06-19 2000-01-24 工業技術院長 線維芽細胞増殖因子関連ペプチドからなる医薬組成物
US6492333B1 (en) * 1999-04-09 2002-12-10 Osteoscreen, Inc. Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
US20040101488A1 (en) * 2000-03-24 2004-05-27 Balaram Ghosh Method for the prevention of septic shock lethality using curcumin
US6689811B2 (en) * 2001-04-20 2004-02-10 Wake Forest University Method of using caffeic acid phenethyl ester and analogs thereof as radiation sensitizers
JPWO2003011276A1 (ja) * 2001-07-26 2004-11-18 株式会社エムズサイエンス ＮＦκＢ阻害剤
US20030139458A1 (en) * 2001-12-10 2003-07-24 Yansheng Du Treatment of neurodegenerative and cardiovascular disorders
WO2003090681A2 (en) * 2002-04-24 2003-11-06 Research Development Foundation SYNERGISTIC EFFECTS OF NUCLEAR TRANSCRIPTION FACTOR NF-κB INHIBITORS AND ANTI-NEOPLASTIC AGENTS
WO2005092322A1 (ja) * 2004-03-29 2005-10-06 Japan Health Sciences Foundation Ｒａｒ活性化を起こす天然化合物
DE102004026045A1 (de) * 2004-05-25 2005-12-22 Universität Ulm Inhibitor für den nukleären Transkriptionsfaktor kappa B(NFxb)
US20100009395A1 (en) * 2006-07-26 2010-01-14 Ramanujam Rama P Luminescence assay utilizing a genetically modified cell line
WO2008062466A2 (en) * 2006-10-13 2008-05-29 Reliance Life Sciences Pvt. Ltd. Cinnamic acid, vanillic acid and benzofuran derivatives for use in the treatment of inflammation and cancer
WO2008083389A1 (en) * 2006-12-29 2008-07-10 Moleculin, L.L.C. Methods of treating skin disorders with caffeic acid analogs
DE102007035642A1 (de) * 2007-07-30 2009-02-12 Grietje Beck Substanzen zur Protektion von Zellen und Geweben gegen Schädigung durch ungünstige Bedingungen
US8450337B2 (en) * 2008-09-30 2013-05-28 Moleculin, Llc Methods of treating skin disorders with caffeic acid analogs
CN102198125B (zh) * 2010-12-10 2013-02-20 南京埃匹卡生物科技有限公司 咖啡酸苯乙酯类衍生物在制备抗肿瘤血管形成的药物中的用途
CN114432423A (zh) * 2014-09-26 2022-05-06 拉金德拉·萨哈伊·巴特纳格尔 用于治疗疾病和病症的NFkB活性的抑制剂
KR101702897B1 (ko) * 2016-04-15 2017-02-06 가톨릭대학교 산학협력단 바이오틴이 결합된 카페인산 화합물을 유효성분으로 함유하는 통풍 예방 또는 치료용 조성물
WO2019075549A1 (en) * 2017-10-20 2019-04-25 University Of New Brunswick COMPOSITIONS AND METHODS FOR INHIBITING CELL GROWTH OF BLOOD CANCER
WO2021179094A1 (en) * 2020-03-13 2021-09-16 University Of New Brunswick Composition and use of a caffeic acid phenethyl ester (cape) compound to treat cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5008441A (en) * 1987-08-04 1991-04-16 The Trustees Of Columbia University In The City Of New York Caffeic acid esters and methods of producing and using same
US4939149A (en) * 1988-10-24 1990-07-03 The United States Of America As Represented By The Department Of Health And Human Services Resiniferatoxin and analogues thereof to cause sensory afferent C-fiber and thermoregulatory desensitization
US5021450A (en) * 1989-05-30 1991-06-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services New class of compounds having a variable spectrum of activities for capsaicin-like responses, compositions and uses thereof
US5306724A (en) * 1992-08-17 1994-04-26 Clintec Nutrition Company Method for preventing and treating atherosclerosis
US5646185A (en) * 1993-10-14 1997-07-08 The Board Of Trustees Of The Leland Stanford Junior University Tumor treatment method
US5591773A (en) * 1994-03-14 1997-01-07 The Trustees Of Columbia University In The City Of New York Inhibition of cataract formation, diseases resulting from oxidative stress, and HIV replication by caffeic acid esters
FR2728793A1 (fr) * 1994-12-28 1996-07-05 Oreal Utilisation d'un antagoniste d'histamine, d'un antagoniste d'interleukine 1 et/ou d'un antagoniste de tnf-alpha dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue

Also Published As

Publication number Publication date
AU4249497A (en) 1998-03-26
CN1810958A (zh) 2006-08-02
WO1998009620A1 (en) 1998-03-12
CA2264739A1 (en) 1998-03-12
JP3987120B2 (ja) 2007-10-03
CN1132577C (zh) 2003-12-31
CA2264739C (en) 2008-03-18
EP0998275A4 (en) 2003-05-02
CN1233171A (zh) 1999-10-27
EP0998275A1 (en) 2000-05-10
US5981583A (en) 1999-11-09
CN100413961C (zh) 2008-08-27
JP2001523085A (ja) 2001-11-20

Similar Documents

Publication Publication Date Title
ZA977992B (en) Inhibition of Nuclear Transcription Factor NF-kB by Caffeic Acid Phenethyl Ester (CAPE), Derivatives of CAPE, Capsaicin (8-methyl-N-Vanillyl-6-noneamide) and Resiniferatoxin.
PL348969A1 (en) Inhibitors of transcription factor nf-κb
ZA977830B (en) Retinoid inhibition of expression of VEGF.
AU2948595A (en) Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
HU9203033D0 (en) Inhibitors of leucotriene biosynthesis
ZA9710015B (en) Nitric oxide donor compounds and pharmaceutical compositions for pulmonary hypertension and other indications.
IL128189A0 (en) Arylsulfonylamino hydroxamic acid derivatives
HUP0002869A3 (en) Benzothiophenecarboxamide derivatives, pharmaceutical compositions thereof and intermediates
HUP9903687A3 (en) Arylsulfonylamino carboxylic and hidroxamic acid derivatives and pharmaceutical compositions with metalloproteinase inhibitory activity containing them
PL331900A1 (en) 1,4-heterocyclic inhibitors of metaloprotease
PH31545A (en) Inhibition of helicobacter.
EP0520336A3 (en) Aldehyde derivatives and their use as calpain inhibitors
ZA974505B (en) Sprout inhibition compositions comprising chlorpropham and substituted naphthalenes and methods of using same.
ZA971964B (en) Azolobenzazepine derivatives and compositions and method of use thereof.
AU4083997A (en) Gata-6 transcription factor: compositions and methods
HUP0100597A3 (en) Hydroxamic and carboxylic acid derivatives
ZA964129B (en) N-acyl-2-aryl cyclopropylmethylamine derivatives as melatonerigics
IL140324A0 (en) Inhibition of transcription factor nf-kb
PL331263A1 (en) Derivatives of glyoxylic acid
AU7398794A (en) 7-substituted-delta4-6-azasteroid derivatives as 5alpha-reductase inhibitors
ZA9710989B (en) Polyprolyl inhibitors of cyclophilin
IL129166A0 (en) Hydroxamic acid derivatives
ZA974683B (en) Oxime derivatives of fenamates as inhibitors of prostaglandin biosynthesis.
IL140861A0 (en) Dioxolane derivatives and processess for the preparation of (s) -2-amino-6,6- dimethoxythexanoic acid methyl ester utilizing the same
EP0877833A4 (en) ALUMINUM DEOXIDATION INHIBITOR, COMPOSITION AND METHOD